Pinealon

01 What is Pinealon?

Pinealon (EDR — glutamic acid-aspartic acid-arginine) is a synthetic tripeptide bioregulator developed by Khavinson's group, designed to target pineal gland function. If your internal clock feels permanently jet-lagged — if you cannot fall asleep at a reasonable hour, wake unrested, or have lost the normal circadian melatonin surge — Pinealon may be relevant. The concept behind peptide bioregulators is that specific short peptides can target specific organs, restoring gene expression toward youthful function. Pinealon is the pineal-specific peptide — it normalises melatonin synthesis and secretion patterns that degrade with age or chronic stress. Unlike taking melatonin directly (which can suppress your own production over time), Pinealon aims to restore your endogenous melatonin rhythm. This distinction matters. Exogenous melatonin replaces your signal. Pinealon theoretically restores your ability to generate the signal. For people whose circadian disruption stems from pineal dysfunction rather than simple behavioural factors, this could be more sustainable long-term.

02 How Does It Work?

Pinealon (EDR) penetrates cell membranes and interacts with DNA in pinealocytes (pineal gland cells), modulating gene expression related to: 1. Melatonin synthesis enzymes (AANAT, HIOMT) — restoring the enzymatic machinery for melatonin production. 2. Serotonin-to-melatonin conversion — optimising the precursor pathway. 3. Circadian gene expression — potentially resetting peripheral clock genes. 4. Neuroprotective pathways — EDR has shown cytoprotective effects on neurons independent of its pineal effects. Being a tripeptide, it can potentially cross the blood-brain barrier and act directly on central nervous system tissue.

03 What Does The Research Say?

Russian research (Khavinson group): Studies showing normalisation of melatonin levels in elderly subjects, improved sleep quality, and restoration of circadian rhythm parameters. Cell culture studies confirm gene expression changes in pinealocytes. Neuroprotection: In vitro studies show EDR protects cortical neurons against oxidative stress and amyloid-beta toxicity — suggesting benefits beyond sleep. Limitations: Almost all research is from the Khavinson group. No independent Western replication. Methodological standards differ from modern Western clinical trials. The concept is biologically plausible but under-validated by Western standards.

04 Reported Dosages

Oral/sublingual: Available in capsule form as a peptide bioregulator supplement (Khavinson peptide products). Typical dose: 1-2 capsules daily for 30 days, cycled. Injectable: Some sources offer EDR for subcutaneous injection at 1-5mg doses. Best taken in evening given its circadian-targeting mechanism. DISCLAIMER: Not approved by Western regulatory agencies. Dosing from Russian research and product labelling. Long-term human safety data is limited.

05 Side Effects & Risks

Minimal reported side effects. As a short peptide bioregulator, systemic toxicity risk is considered low. Possible: vivid dreams (as melatonin production increases), temporary sleep pattern adjustment, mild drowsiness. If you already have healthy pineal function and normal melatonin, the benefit may be minimal.

06 Legal Status